Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmpeak Energy Regulatory News (AMP)

Share Price Information for Ampeak Energy (AMP)

Share Price is delayed by 15 minutes
Get Live Data
3.00    0.30 (11.11%)
Bid:
2.80
Ask:
3.20
Spread: 0.40 (14.286%)
Market Cap: £21.68m
AMP Live PriceLast checked at - London Stock Exchange

Intraday Ampeak Energy Share Chart

Additional Draw Down on Loan Facility

22 Aug 2016 15:58

RNS Number : 8230H
Amphion Innovations PLC
22 August 2016
 

Amphion Innovations plc

 ("Amphion" or "the Company")

Additional Draw Down on Loan Facility

 

London and New York, 22 August 2016 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, today announces that the Company has agreed terms for the draw-down of an additional tranche of US $2,350,000 (an "Additional Draw") under the loan facility as announced on 5 June 2014 (the "Facility").

Under the terms of the Additional Draw, the interest rate will be 10% with repayments starting on 1 January 2017 and with the final repayment due on 1 December 2017. The proceeds are to be used to repay the existing amount due under the Facility and for working capital for Amphion and its Partner Companies.

The loan is secured by the pledge by the Company of 8,754,255 ordinary shares of Kromek Group plc and 27,961,625 ordinary shares of Motif Bio plc.

The current loan balance under the Facility after the Additional Draw will be US $6,198,333. Of this amount, US $3,000,000, plus interest is convertible into the ordinary shares of Amphion Innovations plc at 6 pence and the remaining amount, plus interest is convertible at 8 pence.

Richard Morgan, CEO of Amphion, said: "We continue to believe in the future upside potential of our holdings in our Partner Companies. We are working on moving other programmes forward and this facility gives us access to additional working capital to help develop the emerging companies and to progress the pipeline."

 

 

For further information please contact:

 

Amphion InnovationsCharlie Morgan+1 212 210 6224Yellow Jersey PR

Charles Goodwin / Dominic Barretto+44 (0)7747 788 221Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Freddy Crossley / Duncan Monteith (Corporate Finance)Charlie Leigh-Pemberton (Corporate Broking)+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker) Patrick Claridge / David Hignell (Corporate Finance)John Howes (Corporate Broking)+44 (0)20 7382 1100

Plumtree Capital Limited (Financial Adviser)Stephen Austin+44 (0)20 7183 2493+646 568 7502

 

About Amphion Innovations plc

 

Amphion Innovations is a developer of medical, life science and technology businesses.

 

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

 

On the web: www.amphionplc.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBSGDIUUDBGLD
Date   Source Headline
1st Jul 201312:02 pmRNSDirector/PDMR Shareholding
28th Jun 20137:00 amRNSFinal Results
18th Apr 20137:00 amRNSDirector/PDMR Shareholding
17th Apr 20137:00 amRNSTrading Statement
28th Mar 20137:02 amRNSChange of Adviser
19th Dec 20127:00 amRNSHolding(s) in Company
13th Dec 20127:00 amRNSFundraising
5th Dec 20127:00 amRNSAmphion announces new partnership with Motif
3rd Oct 20127:00 amRNSDirector/PDMR Shareholding
28th Sep 20124:24 pmRNSDirector/PDMR Shareholding
19th Sep 20127:00 amRNSHalf Yearly Report
29th Aug 20127:00 amRNSUpdate - patent litigation
27th Jul 20127:00 amRNSResult of AGM
23rd Jul 20127:00 amRNSDirectors Dealings
20th Jul 201212:00 pmRNSFunding Update
20th Jul 20127:00 amRNSTrading Statement
11th Jun 20127:00 amRNSFinal Results
9th May 20129:20 amRNSFunding update
1st May 20127:00 amRNSPartner Company Update
28th Mar 20127:00 amRNSPartner Company Update
28th Feb 20127:00 amRNSDirector Dealings
23rd Feb 20124:36 pmRNSFunding Update
3rd Feb 20123:24 pmRNSFunding Update
2nd Feb 20127:00 amRNSPatent Approval
30th Dec 20117:00 amRNSDirector Dealings
6th Dec 20119:09 amRNSDirector/PDMR Shareholding
21st Nov 20118:42 amRNSNew Suits Filed and New Debt Facilites
29th Sep 20117:00 amRNSHalf Yearly Report
21st Sep 20117:00 amRNSNotice of Results
9th Sep 20117:00 amRNSIssue of Equity
2nd Aug 20117:00 amRNSTrading Statement
28th Jul 20117:00 amRNSAdjournment of AGM
22nd Jul 20118:20 amRNSDirector/PDMR Shareholding
21st Jul 20119:03 amRNSDirector/PDMR Shareholding
30th Jun 20117:00 amRNSFinal Results
21st Jun 20114:44 pmRNSNew Debt Facility
24th May 20117:00 amRNSDisposal
15th Apr 20119:19 amRNSNew debt facility
14th Apr 20117:00 amRNSNotice of Results
13th Apr 20117:00 amRNSUpdate on Data Tern Patent Litigation
30th Mar 20117:00 amRNSIP Licences and Directorate Change
28th Feb 20117:00 amRNSTrading Statement
6th Jan 20117:00 amRNSChange of Adviser
5th Jan 20117:00 amRNSIP License Agreements
9th Dec 20107:00 amRNSNew Debt Facility
25th Oct 20107:00 amRNSPartner Update
18th Oct 20103:50 pmRNSDirector/PDMR Shareholding
30th Sep 20104:19 pmRNSTotal Voting Rights
24th Sep 20107:00 amRNSIP Licensing
22nd Sep 20108:00 amRNSGrant Win by Partner Company Firestar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.